Education
About Us
Working with TipRanks
Follow Us
Chemomab Therapeutics Ltd. (DE:2QV0)
:2QV0
RESEARCH TOOLSreports
2QV0 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.57 - €2.32
Previous CloseN/A
Volume0.00
Average Volume (3M)561.00
Market Cap
€21.66M
Enterprise Value€8.41M
Total Cash (Recent Filing)$6.07M
Total Debt (Recent Filing)$324.00K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 08, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding18,856,611
10 Day Avg. Volume0
30 Day Avg. Volume561
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
€7.89Price Target Upside644.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Chemomab Therapeutics News
PremiumCompany Announcements
Chemomab Announces Key Leadership Changes Amid Successful Trial Completion
PremiumCompany Announcements
Chemomab’s Nebokitug Shows Promising Phase 2 Results for PSC
PremiumCompany Announcements
Chemomab Therapeutics Updates ADS Offering Under Sales AgreementPremiumCompany Announcements
Chemomab Therapeutics Reports 2024 Financial Results and Progress---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsChemomab reported positive data from the open-label extension study of nebokitug in primary sclerosing cholangitis, showing improvements in key biomarkers related to disease progression.
Financial StabilityThe completion of a $10M equity financing with institutional investors provides financial stability through key milestones and extends the runway into early 2026.
Regulatory ApprovalThe feedback from FDA supports a single Phase 3 for full approval based on events relating to disease progression, with no biopsy endpoint.
Bears Say
Financial PerformanceChemomab reported a net loss of ($3.5M), although it currently has $19.5M in cash.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
21.19% Other Institutional Investors
78.81% Public Companies and
Individual Investors
2QV0 FAQ
What was Chemomab Therapeutics Ltd.’s price range in the past 12 months?
Chemomab Therapeutics Ltd. lowest stock price was €0.57 and its highest was €2.32 in the past 12 months.
What is Chemomab Therapeutics Ltd.’s market cap?
Chemomab Therapeutics Ltd.’s market cap is €21.66M.
When is Chemomab Therapeutics Ltd.’s upcoming earnings report date?
Chemomab Therapeutics Ltd.’s upcoming earnings report date is May 08, 2025 which is in 11 days.
How were Chemomab Therapeutics Ltd.’s earnings last quarter?
Chemomab Therapeutics Ltd. released its earnings results on Mar 03, 2025. The company reported -€0.007 earnings per share for the quarter, beating the consensus estimate of -€0.05 by €0.043.
Is Chemomab Therapeutics Ltd. overvalued?
According to Wall Street analysts Chemomab Therapeutics Ltd.’s price is currently Undervalued.
Does Chemomab Therapeutics Ltd. pay dividends?
Chemomab Therapeutics Ltd. does not currently pay dividends.
What is Chemomab Therapeutics Ltd.’s EPS estimate?
Chemomab Therapeutics Ltd.’s EPS estimate is >-0.01.
How many shares outstanding does Chemomab Therapeutics Ltd. have?
Chemomab Therapeutics Ltd. has 18,856,611 shares outstanding.
What happened to Chemomab Therapeutics Ltd.’s price movement after its last earnings report?
Chemomab Therapeutics Ltd. reported an EPS of -€0.007 in its last earnings report, beating expectations of -€0.05. Following the earnings report the stock price went up 4.054%.
Which hedge fund is a major shareholder of Chemomab Therapeutics Ltd.?
Currently, no hedge funds are holding shares in DE:2QV0
---
Chemomab Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.89 (644.37% Upside)
€7.89 (644.37% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
98.78%
12-Months-Change
Fundamentals
Return on Equity
-91.76%
Trailing 12-Months
Asset Growth
-23.42%
Trailing 12-Months
Company Description
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
---
2QV0 Stock 12 Month Forecast
Average Price Target
€7.89
▲(644.37% Upside)
Technical Analysis
Best Analysts Covering 2QV0
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-34.44%
reiterated a buy rating 2 months ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -34.44% per trade.
---